Advanced Treatment Techniques of Stereotactic, Adaptive and Protons for Gynecologic Cancer – Tips, Tricks and Patient Selection
This activity discusses some of the newer treatment techniques, including stereotactic body radiation (SBRT), adaptive radiation therapy and protons being utilized in gynecologic cancer.
Category
  • Adaptive RT
  • Gynecologic
  • Oligometastatic
Format
  • Sessions onDemand
Credits
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Certificate of Attendance
Cost $149.00
Leveraging Anti-Tumor Immunity with Radiopharmaceutical Therapy (RPT) and Potential Combinatorial Approaches with RPT and Immunotherapy
Radiopharmaceutical Therapy (RPT) is an emerging modality with significant potential to impact future oncological management across many disease settings.
Category
  • Radiopharmaceutical Therapy
Format
  • Sessions onDemand
Credits
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 Certificate of Attendance
Cost $149.00
Optimizing Sequencing in Immunotherapy and Radiotherapy for Non-Small Cell Lung Cancer – Clinical and Translational Advances
This combined immunotherapy track and lung cancer track brings together leading experts to discuss recent, cutting-edge trials and strategies in treating both locally advanced and metastatic non-small cell lung cancer (NSCLC). Dr.
Category
  • Immunotherapy
  • Thoracic
Format
  • Sessions onDemand
Credits
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 Certificate of Attendance
Cost $149.00
Multidisciplinary Lung Cancer Tumor Board: A Case-Based Discussion Spanning Bread-and-Butter through the Gray Zone
The management of locally advanced lung cancer increasingly relies on multidisciplinary collaboration. Advances in neoadjuvant and perioperative chemoimmunotherapy have significantly improved outcomes for patients with resectable non-small cell lung cancer.
Category
  • Thoracic
Format
  • Sessions onDemand
Credits
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Certificate of Attendance
Cost $149.00
Neoadjuvant Immunotherapy in Head and Neck Cancer, Sarcoma and Cutaneous Malignancies
Recent landmark studies in melanoma, cutaneous squamous cell carcinoma (cSCC), head and neck cancer (HNC) and sarcoma have established neoadjuvant immune therapy as a potential standard of care for patients with locally advanced cancers.
Category
  • Head and Neck
  • Immunotherapy
  • Sarcoma
Format
  • Sessions onDemand
Credits
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 Certificate of Attendance
Cost $149.00
Contingency Planning for Disruptions Due to Loss of Hardware and/or Software Functionality
Extended disruptions in treatment capabilities due to unforeseen events — such as cyberattacks or equipment failures — pose significant challenges for radiotherapy departments.
Category
  • General RO
  • Professional Development
Format
  • Sessions onDemand
Credits
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Certificate of Attendance
Cost $49.00
Management of Locally Recurrent Head and Neck Cancer
Locally recurrent HNSCC in the setting of prior radiation therapy is a challenging clinical scenario.
Category
  • Head and Neck
Format
  • Sessions onDemand
Credits
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Certificate of Attendance
Cost $0.00
Evolving Multidisciplinary Management of Patients with Esophageal and Gastroesophageal Junction Cancer
The treatment landscape of esophageal and gastroesophageal junction cancer is evolving quickly with changes in the role of surgical management, emerging clinical data on the use of chemoradiation vs.
Category
  • Gastrointestinal
Format
  • Sessions onDemand
Credits
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 Certificate of Attendance
Cost $149.00
Integrating Radiation Therapy with Novel Immunotherapies in the Management of Brain Metastases and Leptomeningeal Disease
With improved systemic therapy, the management of brain metastasis has become increasingly important. A number of immunotherapies and targeted agents have shown blood brain barrier penetration with a potential role in the upfront management of brain metastases and leptomeningeal disease.
Category
  • Central Nervous System
  • Immunotherapy
Format
  • Sessions onDemand
Credits
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Certificate of Attendance
Cost $149.00
ASTRO/SNO Joint Activity: Current Multidisciplinary Management of Molecularly Defined IDH Mutant Grade 2 - 3 Glioma - Who, What, When, Why and How?
The management of patients with grade 2 – 3 glioma has recently become even more complicated due to incorporation of molecular findings for pathologic diagnosis, changing criteria for who is considered high risk, and variability in the use and choice of chemotherapy with radiotherapy.
Category
  • Central Nervous System
Format
  • Sessions onDemand
Credits
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Certificate of Attendance
Cost $149.00

Pages